MedTrace Logo

Rates and Severity of PONV for Neuromuscular Block Reversal in Patients Receiving Gastric Bypass Bariatric Surgery

NCT03432845 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-10-03

No results posted yet for this study

Summary

Patients who require bariatric surgery frequently bring a panoply of pre-existing comorbidities to the operating theatre. With body mass indices routinely in the 50s and 60s, patients who have bariatric surgery frequently have postoperative and post-discharge nausea and vomiting (PONV and PDNV)

Conditions

  • Bariatric Surgery Candidate

Interventions

OTHER

compare reversal agents

compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting

Sponsors & Collaborators

  • WellSpan Health

    lead OTHER

Principal Investigators

  • Rich Haas, PhD · Principal Investigator

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-12-31
Completion
2019-03-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03432845 on ClinicalTrials.gov